121 related articles for article (PubMed ID: 37278580)
61. Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia.
Kalra M; Dinand V; Choudhary S; Sachdeva A; Yadav SP
Indian Pediatr; 2013 Jul; 50(7):659-62. PubMed ID: 23502666
[TBL] [Abstract][Full Text] [Related]
62. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.
Roy Moulik N; Kumar A; Agrawal S; Awasthi S; Mahdi AA; Kumar A
Leuk Lymphoma; 2015 May; 56(5):1379-84. PubMed ID: 25065700
[TBL] [Abstract][Full Text] [Related]
63. Benefit of oral nutritional supplements for children with acute lymphoblastic leukaemia during remission-induction chemotherapy: a quasi-experimental study.
Liang R; Chen GY; Fu SX; Zhong J; Ma Y
Asia Pac J Clin Nutr; 2018; 27(1):144-147. PubMed ID: 29222892
[TBL] [Abstract][Full Text] [Related]
64. Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study.
Bruzzi P; Predieri B; Corrias A; Marsciani A; Street ME; Rossidivita A; Paolucci P; Iughetti L
BMC Pediatr; 2014 Sep; 14():236. PubMed ID: 25245636
[TBL] [Abstract][Full Text] [Related]
65. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Orgel E; Sposto R; Malvar J; Seibel NL; Ladas E; Gaynon PS; Freyer DR
J Clin Oncol; 2014 May; 32(13):1331-7. PubMed ID: 24687836
[TBL] [Abstract][Full Text] [Related]
66. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
Reiter A; Schrappe M; Ludwig WD; Tiemann M; Parwaresch R; Zimmermann M; Schirg E; Henze G; Schellong G; Gadner H; Riehm H
Blood; 2000 Jan; 95(2):416-21. PubMed ID: 10627444
[TBL] [Abstract][Full Text] [Related]
67. Body mass trajectory from diagnosis to the end of treatment in a pediatric acute lymphoblastic leukemia cohort.
Galati PC; Rocha PRS; Gruezo ND; Amato AA
Sci Rep; 2023 Aug; 13(1):13590. PubMed ID: 37604919
[TBL] [Abstract][Full Text] [Related]
68. Effects of malnutrition on oxidative burst functions and infection episodes in children with acute lymphoblastic leukemia.
Cakir FB; Aydogan G; Timur C; Canpolat C; Tulunay A; Eksioglu Demiralp E; Berrak SG
Int J Lab Hematol; 2012 Dec; 34(6):648-54. PubMed ID: 22830439
[TBL] [Abstract][Full Text] [Related]
69. Does weight for height have prognostic significance in children with acute lymphoblastic leukemia?
Reilly JJ; Odame I; McColl JH; McAllister PJ; Gibson BE; Wharton BA
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):225-30. PubMed ID: 8037340
[TBL] [Abstract][Full Text] [Related]
70. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
Wasserman R; Galili N; Ito Y; Silber JH; Reichard BA; Shane S; Womer RB; Lange B; Rovera G
J Clin Oncol; 1992 Dec; 10(12):1879-88. PubMed ID: 1453203
[TBL] [Abstract][Full Text] [Related]
71. Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group.
Withycombe JS; Smith LM; Meza JL; Merkle C; Faulkner MS; Ritter L; Seibel NL; Moore K
Pediatr Blood Cancer; 2015 Mar; 62(3):434-9. PubMed ID: 25407299
[TBL] [Abstract][Full Text] [Related]
72. Predictors of being overweight or obese in survivors of pediatric acute lymphoblastic leukemia (ALL).
Zhang FF; Rodday AM; Kelly MJ; Must A; MacPherson C; Roberts SB; Saltzman E; Parsons SK
Pediatr Blood Cancer; 2014 Jul; 61(7):1263-9. PubMed ID: 24482072
[TBL] [Abstract][Full Text] [Related]
73. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
74. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
75. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
76. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
[TBL] [Abstract][Full Text] [Related]
77. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
[TBL] [Abstract][Full Text] [Related]
78. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
79. Influence of treatment modalities on body weight in acute lymphoblastic leukemia.
Groot-Loonen JJ; Otten BJ; van't Hof MA; Lippens RJ; Stoelinga GB
Med Pediatr Oncol; 1996 Aug; 27(2):92-7. PubMed ID: 8649326
[TBL] [Abstract][Full Text] [Related]
80. Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/middle income population: A multi-institutional report from Pakistan.
Fadoo Z; Nisar I; Yousuf F; Lakhani LS; Ashraf S; Imam U; Zaheer J; Naqvi A; Belgaumi A
Pediatr Blood Cancer; 2015 Oct; 62(10):1700-8. PubMed ID: 25982135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
